[Ip-health] WHA71: KEI intervention on Addressing the global shortage of, and access to, medicines and vaccines

Nicole H nhassoun at binghamton.edu
Mon May 21 05:46:27 PDT 2018

Dear all,

I am not sure if you have seen this resource but we provide information on
some of these things in an easily digestible form for 2010 for malaria, TB,
and HIV/AIDS medicines: global-health-impact.org You can see the patent
holders and impact of medicines. We are working on expanding the index
across time and intervention and providing a better picture of the
pharmaceutical supply chain and may also provide information about the
costs of medicines. HAI also provides some information on prices and I
believe the WHO has a drugs quality database:

All best, Nicole

On Mon, May 21, 2018 at 2:33 AM, Thiru Balasubramaniam <thiru at keionline.org>

> https://www.keionline.org/27884
> KEI intervention on Addressing the global shortage of, and access to,
> medicines and vaccines
> 21 May 2018
> Knowledge Ecology International (KEI) intends to deliver the following
> statement on Addressing the global shortage of, and access to, medicines
> and vaccines: 11.5 Addressing the global shortage of, and access to,
> medicines and vaccines
> The Road Map report is WHO’s work program on access to medicines and
> vaccines which deals with issues that have several dimensions, including at
> the center, the global set of incentives and funding mechanisms for
> research and development to simulate the development of new drugs,
> vaccines, diagnostics and new cell and gene therapies.
> To evaluate the impact of the current system and any proposed reforms, both
> incremental and transformative, on innovation and access, the twin and
> currently conflicting objectives, it is important to have better evidence
> regarding the costs of R&D of specific products and services, in a level of
> disaggregation sufficient to adequately analyze the risks associated with
> development. It is also important to have better and more transparent
> information on resource flows by research targets, data on actual access by
> country, the annual and cumulative revenue from sales, as well as greater
> transparency and better information on a host of other issues, such as
> prices, patent and registration landscapes, the use of exceptions and
> limitations to intellectual property rights, the texts of proposed trade
> agreements that are relevant to innovation and access to medical
> technologies.
> There is a need to fix the current failures to obtain competition for
> biologic drugs. Recent data in the US show that biologic drugs first
> registered between 1995 and 2005 faced competition for products with the
> same pharmaceutical active agreement only 17 percent of the time, compared
> to 61 percent for small molecules, and when competition did occur, it
> happened 6 years later, and only resulted in an average of 1.5 competitors.
> Finally, we must admit that we cannot effectively regulate big drug
> monopolies in the public interest, and it is time to advance work on the
> delinkage of R&D funding including incentives from the prices of goods and
> services.
> --
> Thiru Balasubramaniam
> Geneva Representative
> Knowledge Ecology International
> 41 22 791 6727
> thiru at keionline.org
> _______________________________________________
> Ip-health mailing list
> Ip-health at lists.keionline.org
> http://lists.keionline.org/mailman/listinfo/ip-health_lists.keionline.org

Nicole Hassoun
Visiting Scholar
Cornell University
218 Goldwin Smith Hall
Ithaca, New York 14853-3201
Associate Professor
Binghamton University
Department of Philosophy
4400 Vestal Parkway East
Box 6000
Binghamton, NY 13902-6000
Website: http://harvey.binghamton.edu/~nhassoun/faculty-hassoun.php

More information about the Ip-health mailing list